- Home
- NVR vs DGX Comparison
NVR vs DGX Comparison
Compare NVR & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVR
- DGX
- Stock Information
- Founded
- NVR 1980
- DGX 1967
- Country
- NVR United States
- DGX United States
- Employees
- NVR N/A
- DGX N/A
- Industry
- NVR Homebuilding
- DGX Medical Specialities
- Sector
- NVR Consumer Discretionary
- DGX Health Care
- Exchange
- NVR Nasdaq
- DGX Nasdaq
- Market Cap
- NVR 22.2B
- DGX 20.5B
- IPO Year
- NVR N/A
- DGX 1996
- Fundamental
- Price
- NVR $7,702.79
- DGX $180.99
- Analyst Decision
- NVR Buy
- DGX Buy
- Analyst Count
- NVR 4
- DGX 15
- Target Price
- NVR $8,250.00
- DGX $188.47
- AVG Volume (30 Days)
- NVR 21.2K
- DGX 1.0M
- Earning Date
- NVR 10-23-2025
- DGX 10-21-2025
- Dividend Yield
- NVR N/A
- DGX 1.73%
- EPS Growth
- NVR N/A
- DGX 14.49
- EPS
- NVR 474.94
- DGX 8.52
- Revenue
- NVR $10,717,672,000.00
- DGX $10,850,000,000.00
- Revenue This Year
- NVR N/A
- DGX $11.13
- Revenue Next Year
- NVR N/A
- DGX $3.41
- P/E Ratio
- NVR $16.41
- DGX $21.68
- Revenue Growth
- NVR 5.86
- DGX 13.74
- 52 Week Low
- NVR $6,562.85
- DGX $146.91
- 52 Week High
- NVR $9,867.00
- DGX $197.55
- Technical
- Relative Strength Index (RSI)
- NVR 44.51
- DGX 44.46
- Support Level
- NVR $7,600.22
- DGX $179.86
- Resistance Level
- NVR $7,827.92
- DGX $197.55
- Average True Range (ATR)
- NVR 168.68
- DGX 4.09
- MACD
- NVR -2.14
- DGX -0.11
- Stochastic Oscillator
- NVR 34.28
- DGX 17.83
About NVR NVR Inc.
NVR Inc is a United States-based homebuilding company. It builds single-family detached homes, townhomes, and condominium buildings under three brands, Ryan Homes, NVHomes, and Heartland Homes. The company through its subsidiary also operates a mortgage banking and title services business. The homebuilding segment includes four geographic areas of the Mid-Atlantic, North East, Mid-East, and South East.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.